Literature DB >> 62714

Fibroblast lysis by lymphocytes from normal persons and SLE patients on short-term cultures.

E M Liburd, V Pazderka, A S Russell, J B Dossetor.   

Abstract

Lymphocytes from thirty-six normal individuals of both sexes with ages ranging from 4-89 years were tested for their cytotoxic activity against short term cluters of fibroblasts from nine foetal umbilical cords and nine adult skin samples. Wide variability in the amount of fibroblast lysis was observed. Adult male lymphocytes caused significantly higher lytic activity than lymphocytes of adult females against both types of targets. Cell-mediated target cell reduction was not confined to allogeneic target cells. There was also killing of autochthonous cultured fibroblasts. Some individuals' sera inhibited the fibroblast lytic activity of their own lymphocytes. These cell-mediated reactions are directed against unknown antigenic specifications, probably not histocompatibility antigens, and give evidence of the problem of how to measure normal controls in the microcytotoxicity test in allogeneic human testing. Both autochthonous and allogeneic target cell lysis were also observed in SLE patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62714      PMCID: PMC1445146     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  9 in total

1.  Problems in the clinical use of the microcytotoxicity assay for measuring cell-mediated immunity to tumor cells.

Authors:  G Heppner; E Henry; L Stolbach; F Cummings; E McDonough; P Calabresi
Journal:  Cancer Res       Date:  1975-08       Impact factor: 12.701

Review 2.  Cytotoxic effects of lymphoid cells in vitro.

Authors:  P Perlmann; G Holm
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

3.  Lymphocyte cytotoxicity in bladder cancer. No requirement for thymus-derived effector cells?

Authors:  C O'Toole; P Perlmann; H Wigzell; B Unsgaard; C G Zetterlund
Journal:  Lancet       Date:  1973-05-19       Impact factor: 79.321

4.  Cellular and humoral immunity to different types of human neoplasms.

Authors:  I Hellström; K E Hellström; G E Pierce; J P Yang
Journal:  Nature       Date:  1968-12-28       Impact factor: 49.962

5.  Humoral and cell-mediated immunity in transfused uraemics.

Authors:  J B Dossetor; T Kovithavongs; V S Lao; E M Liburd; J F Lockwood; J Schlaut; L A Olson; C R Stiller
Journal:  Proc Eur Dial Transplant Assoc       Date:  1973

6.  Spleen cell cytotoxicity in New Zealand black mice (NZB) with autoimmune disease.

Authors:  E M Liburd; A S Russell; J B Dossetor
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

7.  Reactivity of lymphocytes from normal persons on cultured tumor cells.

Authors:  M Takasugi; M R Mickey; P I Terasaki
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

8.  Microcytotoxicity assays of tumor immunity in patients with bronchogenic carcinoma correlated with clinical status.

Authors:  G E Pierce; B DeVald
Journal:  Cancer Res       Date:  1975-12       Impact factor: 12.701

9.  Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms.

Authors:  I Hellström; H O Sjögren; G Warner; K E Hellström
Journal:  Int J Cancer       Date:  1971-03-15       Impact factor: 7.396

  9 in total
  3 in total

1.  Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes.

Authors:  L H Perrin; R M Zinkernagel; M B Oldstone
Journal:  J Exp Med       Date:  1977-10-01       Impact factor: 14.307

2.  Antibody-dependent and phytohaemagglutinin-induced lymphocyte cytotoxicity in systemic lupus erythematosus.

Authors:  J K Wright; P Hughes; K Gelsthorpe; A M Ward; N R Rowell
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

3.  Postnatal expansion of the natural killer and keller cell population in humans identified by the monoclonal HNK-1 antibody.

Authors:  T Abo; M D Cooper; C M Balch
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.